The prevalence and prognostic significance of KRAS mutation subtypes in lung adenocarcinomas from Chinese populations

Abstract

BackgroundWe performed this retrospective study to identify the prevalence of KRAS mutation in Chinese populations and make a comprehensive investigation of the clinicopathological features of KRAS mutation in these patients.Patients and methodsPatients from 2007 to 2013 diagnosed with primary lung adeno-carcinoma who received a radical resection were examined for KRAS, EGFR, HER2, BRAF mutations, and ALK, RET, and ROS1 fusions. Clinicopathological features, including sex, age, tumor–lymph node–metastasis stage, tumor differentiation, smoking status, histological subtypes, and survival information were analyzed.ResultKRAS mutation was detected in 113 of 1,368 patients. Nine different subtypes of KRAS mutation were identified in codon 12, codon 13, and codon 61. KRAS mutation was more frequently found in male patients and former/current smoker patients. Tumors with KRAS mutation had poorer differentiation. Invasive mucinous adenocarcinoma predominant and solid predominant subtypes were more frequent in KRAS mutant patients. No statistical significance was found in relapse-free survival or overall survival between patients with KRAS mutation and patients with other mutations.ConclusionIn Chinese populations, we identified KRAS mutation in 8.3% (113/1,368) of the patients with lung adenocarcinoma. KRAS mutation defines a molecular subset of lung adenocarcinoma with unique clinicopathological features.

Targeted sequencing reveals distinct pathogenic variants in Chinese patients with lung adenocarcinoma brain metastases

“…The prevalence of KRAS mutations in the present study was less than that observed in the Caucasian group. Similarly, a recent study also identified KRAS mutations in 8.3% (113/1,368) of a patient cohort with LC (31). In the present study, BRAF and PIK3CA mutations were identified in a small proportion of patients with LCBM, however were not exhibited in patients with LC.…”

Prognostic value of <em>EGFR</em> and <em>KRAS</em> in resected non-small cell lung cancer: a systematic review and meta-analysis

“…Moreover, the full texts of 38 articles were intensively scrutinized and five studies were excluded due to incomplete data. Finally, 33 studies 11 , 13 , 16 , 17 , 19 – 47 fulfilling all of the inclusion criteria were eligible for meta-analysis. Figure 1 shows the flowchart of the search results.…”

“…The results showed that the 5-year OS of KRAS -mutated NSCLC patients was significantly reduced compared with that of wild-type KRAS patients, and the relapse rate of patients with KRAS mutations increased. However, in a retrospective study 17 assessing KRAS mutations in postoperative NSCLC, the results revealed no significant difference between recurrence-free survival (RFS) and OS in patients with KRAS mutations and wild-type KRAS . Some studies suggest that KRAS mutations are prognostic factors of NSCLC, whereas other studies demonstrate no relationship between KRAS mutations and NSCLC patient survival.…”

Analysis of the clinicopathologic characteristics and prognostic of stage I invasive mucinous adenocarcinoma

“…Heterogeneous mixture of IMA may show with any growth pattern including lepidic, acinar, papillary and micropapillary and solid, which should be classified as "mixed mucinous and nonmucinous adenocarcinoma" (Kadota et al 2014;Travis et al 2011). Genetically, previous studies indicated that IMA was associated with KRAS mutation, and the rate of EGFR mutation was rare when KRAS mutations were present, which predict primary resistance to tyrosine kinase inhibitors (TKIs) (Hata et al 2010;Ichinokawa et al 2013;Massarelli et al 2007;Qu et al 2016;Zheng et al 2016). Clinically, IMA have a tendency for multicentric, multilobar involvement (Travis et al 2011).…”